8-K current report · filed Nov 4, 2026

Vir Biotechnology, Inc. (VIR) 8-K Current Report: November 4, 2026

Item 2.02Item EX-99.1VIR overview

Short answer

Vir Biotechnology, Inc. (VIR) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.

Vir Biotechnology, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Full results and management commentary available in Exhibit 99.1 accompanying the 8-K

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net loss $96.3M, or $0.57 per share, improved from $163.1M, or $1.17, largely due to the prior-year $75.0M milestone expense
  • Cash, equivalents and investments $901.3M after a $106.5M quarterly decline, with operating runway projected into the second half of 2028
  • ECLIPSE 1 Phase 3 topline data expected Q4 2026, creating the next major CHD valuation catalyst
  • Gilead collaboration delivered $90M upfront consideration, with up to $1.74B in additional milestones and tiered royalties
  • VIR-5500 received FDA Fast Track designation and proof of concept, with multiple pivotal oncology trials planned for 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Vir Biotechnology, Inc. 8-K filings

Get the next VIR 8-K as it lands

Follow VIR for push alerts, or ask the research agent what this filing means.